Catalent acquires Pharmapak Technologies, a pharmaceutical packaging company based in New South Wales, Australia.
Catalent announced on March 30, 2014 that it acquired Pharmapak Technologies, a pharmaceutical packaging business based out of New South Wales, Australia. Catalent currently operates a facility in Braeside, Victoria, where it produces oral-dose products to supply throughout Asia Pacific. The acquisition will give Catalent regional packaging options for its local production.
“This acquisition complements our industry-leading oral-dosage form development and manufacturing capabilities with a broader range of packaging options, from bulk supply to finished packs,” said Mark Bisset, president of Catalent Asia Pacific, in a press release. “Catalent has made substantial recent investments in Asia Pacific with a new facility in China, and last year we celebrated our 40th year in Japan with a new laboratory and the build-out of more manufacturing capacity. This latest investment is in response to strong, local market demand for both pharmaceutical, over-the-counter (OTC), and Complementary Medicine products.”
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.